Health Care

The preeminent health care destination for capital markets advice and research coverage

Research capabilities for
Health Care sector

Cowen’s health care equity research is agenda-setting, and our footprint is among the largest. Our analysts’ work has been validated in third-party polls, such as Institutional Investor’s All-America Research Team, the Greenwich Associates poll, and Starmine. In addition to company-specific research, our team publishes over 17,000 pages of industry research annually. Publications such as Biotechnology Quarterly, Pharmaceutical Industry Pulse, Specialty Pharmaceutical Pulse, Therapeutic Categories Outlook, Life Science Tool Kit, and Diagnostics Kit have become legend among investors.


Similarly, our Ahead Of The Curve ™ reports are at the center of conversation.

Our annual Health Care Conference remains one of Wall Street’s most highly regarded, and is the epicenter of discussion for corporate executives, institutional investors, venture capitalists, and health care professionals.

Learn more about our research expertise


General Contact

Robert Fagin
Head of Research
D 646 562 1310

Stephen E. Reilly
Co-director of Research
D 617 946 3901

Lisa Thomas
Associate Director of Research
D 646 562 1388

Investment Banking capabilities for
Health Care sector

Cowen’s health care investment banking Group combines the global resources and full service product capabilities of a leading financial institution with the focus and commitment of a specialty investment banking firm.

Focused on financings and financial advisory for life sciences, medical technology and health care services companies our health care team have developed industry contacts which are leveraged to result in flawless execution and long-term client support.

Learn more about our investment banking expertise


Latest Transactions

  • This funding enables the company to support establishment of translational research and advanced manufacturing capabilities to complement Cabalettas relationship with the Center for Cellular Immunotherapies in the Abramson Center at the University of Pennsylvania (Penn).
  • Viveve Medical expects to use the proceeds to support the continued commercialization of the Companys products in North America and internationally; to obtain additional regulatory clearances; to conduct the VIVEVE II sexual function, LIBERATE-INT and LIBERATE-U.S. SUI clinical trials; and for general corporate and working capital purposes.
  • Quotient Limited intends to use net proceeds from this offering, together with its existing cash and cash equivalents, to fund ongoing scale-up / commercialization of the MosaiQ instrument and for general corporate purposes, including capital expenditures and working capital.


General Contact

George Milstein
Head of Health Care
D 415 646 7394